Mannkind_Logo_RGB_1200x628.png
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
10 mars 2025 06h05 HE | MannKind
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Straits Logo 1-01 (1).png
Cholesterol Test Market Size is Expected to Reach USD 16.10 Billion by 2033, Growing at a CAGR of 7.4%: Straits Research New York, United States, March 06, 2025 (GLOBE NEWSWIRE) -- A cholesterol test, a lipid panel, or a lipid profile is a blood test used to measure cholesterol levels and other fats in the blood. It...
22157.jpg
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
19 févr. 2025 10h09 HE | Research and Markets
Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...
EnVision Health NYC
Inaugural Eye Health Summit Empowers Public with Integrative Vision Care Insights from Leading Experts
19 févr. 2025 09h00 HE | The Eye Health Summit
The Eye Health Summit, a new global patient-centered event dedicated to integrative eye health, will take place May 1–7 as a free hybrid event.
UMeWorld Limited Announces Groundbreaking Study Published in the Journal of Lipid Research, Highlighting the Benefits of Low Triglyceride DAGola Cooking Oil for Athletes
18 févr. 2025 08h00 HE | UMeWorld Limited
UMeWorld announces groundbreaking study on DAGola oil, showing benefits in reducing uric acid and triglycerides for athletes, supporting long-term health.
Pharmacokinetic Profile of Semaglutide in Canines
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
05 févr. 2025 16h05 HE | Rani Therapeutics, LLC
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...
22157.jpg
Type 1 Diabetes 68-Market Analysis and Sales Forecasts 2023-2025 & 2033 Featuring Abbvie, Allergan, Eli Lilly, Pfizer, Sanofi, Novo Nordisk, vTv Therapeutics, Johnson & Johnson, and Adocia
04 févr. 2025 09h20 HE | Research and Markets
Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Type 1 Diabetes: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68...
SABPrimaryLogoColorRGB900px72ppi.png
SAB BIO to Participate in Upcoming Investor Conferences
31 janv. 2025 07h00 HE | SAB Biotherapeutics, Inc.
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...
Shine On_Horiz_redY_blackSO_RGB_Northern Alberta.png
Free diabetes prevention program helps people lower their risk and stay healthy
28 janv. 2025 11h23 HE | YMCA of Northern Alberta
YMCA offers a free diabetes prevention program. Participants can learn more at our wellness day on January 29 at Castle Downs Family YMCA.
SABPrimaryLogoColorRGB900px72ppi.png
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
28 janv. 2025 07h00 HE | SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142